Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Glomulin, FKBP-associated protein (GLMN) is a phosphorylated regulatory protein that is a member of a Skp1-Cullin-F-box-like complex involved in the regulation of ubiquitin-protein ligase activity and protein stability. It is essential for the normal development of vasculature, and mutations in the GLMN gene cause glomuvenous malformations (glomangiomas), a type of vascular tumor. GLMN serves specifically to repress the activity of cullin-RING E3 ubiquitin ligase complexes by binding and sequestering the RING domain protein RBX1, thereby influencing the turnover of key regulatory proteins. Multiple splice variants exist, but the full-length nature of only one has been characterized. GLMN interacts with proteins such as FKBP4 and FKBP1A and participates in pathways including innate immune system function and antigen processing, but it is not currently a direct therapeutic drug target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glomulin, FKBP-associated protein (GLMN).